Show simple item record

dc.contributor.authorCousins, Gráinne
dc.contributor.authorDurand, Louise
dc.contributor.authorO'Kane, Aoife
dc.contributor.authorTierney, Julie
dc.contributor.authorMaguire, Richard
dc.contributor.authorStokes, Siobhán
dc.contributor.authorO'Reilly, Deirdre
dc.contributor.authorArensman, Ella
dc.contributor.authorBennett, Kathleen E
dc.contributor.authorVázquez, María Otero
dc.contributor.authorCorcoran, Paul
dc.contributor.authorLyons, Suzi
dc.contributor.authorKavanagh, Yvonne
dc.contributor.authorKeenan, Eamon
dc.date.accessioned2024-06-27T09:10:10Z
dc.date.available2024-06-27T09:10:10Z
dc.date.issued2023-03-02
dc.identifier.pmid36863742
dc.identifier.doi10.1136/bmjopen-2022-069665
dc.identifier.urihttp://hdl.handle.net/10147/641784
dc.descriptionIntroduction There is an increasing concern about the misuse of prescription drugs. Misuse refers to the intentional repurposing of prescribed drugs and/or the use of illicitly sourced prescription drugs, which may be counterfeit or contaminated. Drugs with the greatest potential for misuse are prescription opioids, gabapentinoids, benzodiazepines, Z-drugs and stimulants. Objective The aim of this study is to provide a comprehensive analysis of the supply, patterns of use and health burden associated with prescription drugs with potential for misuse (PDPM) in Ireland between 2010 and 2020. Three inter-related studies will be carried out. The first study will describe trends in supply of PDPM using law enforcement drug seizures data and national prescription records from national community and prison settings. The second study aims to estimate trends in the detection of PDPM across multiple early warning systems using national forensic toxicology data. The third study aims to quantify the health burden associated with PDPM nationally, using epidemiological indicators of drug-poisoning deaths, non-fatal intentional drug overdose presentations to hospitals and drug treatment demand. Methods and analysis A retrospective observational study design, with repeated cross-sectional analyses, using negative binomial regression models or, where appropriate, joinpoint regression. Ethics and dissemination The study has received approval from the RCSI Ethics Committee (REC202202020). Results will be disseminated in peer-reviewed journals, scientific and drug policy meetings and with key stakeholders via research briefs.en_US
dc.language.isoenen_US
dc.rights© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectFORENSIC MEDICINEen_US
dc.subjectpublic healthen_US
dc.subjectSubstance misuseen_US
dc.subjectSuicide & self-harmen_US
dc.titlePrescription drugs with potential for misuse: protocol for a multi-indicator analysis of supply, detection and the associated health burden in Ireland between 2010 and 2020.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.eissn2044-6055
dc.identifier.journalBMJ openen_US
dc.source.journaltitleBMJ open
dc.source.volume13
dc.source.issue3
dc.source.beginpagee069665
dc.source.endpage
refterms.dateFOA2024-06-27T09:10:13Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
bmjopen-2022-069665.pdf
Size:
403.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Except where otherwise noted, this item's license is described as © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.